Selexipag-d7

Selexipag-d7 is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor) [1][2].

Product Specifications

CAS Number

[1265295-21-3]

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Prostaglandin Receptor

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Others

Field of Research

Cardiovascular Disease; Endocrinology

Purity

98.44

Solubility

10 mM in DMSO|DMSO : ≥ 50mg/mL

Smiles

CS(NC(COCCCCN(C1=CN=C(C2=CC=CC=C2)C(C3=CC=CC=C3)=N1)C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)(=O)=O

Molecular Formula

C26H25D7N4O4S

Molecular Weight

503.66

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Kuwano K, et al. 2-[4-[ (5,6-diphenylpyrazin-2-yl) (isopropyl) amino]butoxy]-N- (methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007 Sep;322 (3) :1181-8.|[3]Mous DS, et al. Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag's active compound, at the pseudoglandular stage improves lung vasculature. Am J Physiol Lung Cell Mol Physiol. 2018 May 10.